Andreas Hottinger

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


112 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2005 | 2000 | 1999 | 1997 | 1994 |
2024
 
Cancer Therapy-Induced Encephalitis.
Desbaillets N.P., Hottinger A.F., 2024/10/23. Cancers, 16 (21). Peer-reviewed.
[DOI][Pmid][serval:BIB_3F26575B1292]
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.
Watson S.S., Zomer A., Fournier N., Lourenco J., Quadroni M., Chryplewicz A., Nassiri S., Aubel P., Avanthay S., Croci D. et al., 2024/09/09. Cancer cell, 42 (9) pp. 1507-1527.e11. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ACA88D313315]
Status epilepticus management in patients with brain tumors. A cohort study.
Tziakouri A., Hottinger A.F., Novy J., Rossetti A.O., 2024/08. Seizure, 120 pp. 1-4. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93536ECC1573]
Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.
Loser V., Segot A., de Leval L., Bisig B., Brouland J.P., Hewer E., Barcena C., Hottinger A.F., Pot C., 2024/07/22. BMC neurology, 24 (1) p. 250. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9D8A4D752094]
 
Hypnosis-Assisted Awake Craniotomy for Eloquent Brain Tumors: Advantages and Pitfalls.
Cossu G., Vandenbulcke A., Zaccarini S., Gaudet J.G., Hottinger A.F., Rimorini N., Potie A., Beaud V., Guerra-Lopez U., Daniel R.T. et al., 2024/05/05. Cancers, 16 (9). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_030D0E6436B5]
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.
Kinj R., Hottinger A.F., Böhlen T.T., Ozsahin M., Vallet V., Dunet V., Bouchaab H., Peters S., Tuleasca C., Bourhis J. et al., 2024/04/29. Cancers, 16 (9). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51F2E37A9F70]
Acute ischaemic stroke in active cancer versus non-cancer patients: stroke characteristics, mechanisms and clinical outcomes.
Costamagna G., Hottinger A.F., Milionis H., Salerno A., Strambo D., Livio F., Navi B.B., Michel P., 2024/04. European journal of neurology, 31 (4) pp. e16200. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33F6C6BB2CCE]
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A., Hottinger A.F., Latifyan S., Boughdad S., Becce F., Prior J.O., Kuntzer T., Brouland J.P., Dunet V., Obeid M. et al., 2024/04. Journal of neurology, 271 (4) pp. 1947-1958. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_29F8761FAE12]
 
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment.
Costamagna G., Navi B.B., Beyeler M., Hottinger A.F., Alberio L., Michel P., 2024/04. Seminars in thrombosis and hemostasis, 50 (3) pp. 342-359. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB89FEB62E93]
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older
Stadler Christina, Gramatzki Dorothee, Le Rhun Emilie, Hottinger Andreas F, Hundsberger Thomas, Roelcke Ulrich, Läubli Heinz, Hofer Silvia, Seystahl Katharina, Wirsching Hans-Georg et al., 2024/03/15. Neuro-Oncology Practice, 11 (2) pp. 132-141.
[URN][DOI][WoS][Pmid][serval:BIB_BCE3F699A54E]
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
Bejarano L., Kauzlaric A., Lamprou E., Lourenco J., Fournier N., Ballabio M., Colotti R., Maas R., Galland S., Massara M. et al., 2024/03/11. Cancer cell, 42 (3) pp. 378-395.e10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AD4E56F8FEC]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M., Roth P., Bink A., Fischer Maranta A., Läubli H., Hottinger A.F., Hundsberger T., Migliorini D., Ochsenbein A., Seystahl K. et al., 2024/01/15. BMC cancer, 24 (1) p. 82. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5EBA66D24C63]
Human stem cell-derived neurons and astrocytes to detect novel auto-reactive IgG response in immune-mediated neurological diseases.
Mathias A., Perriot S., Jones S., Canales M., Bernard-Valnet R., Gimenez M., Torcida N., Oberholster L., Hottinger A.F., Zekeridou A. et al., 2024. Frontiers in immunology, 15 p. 1419712. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_461752E4D09D]
2023
The local microenvironment drives activation of neutrophils in human brain tumors.
Maas R.R., Soukup K., Fournier N., Massara M., Galland S., Kornete M., Wischnewski V., Lourenco J., Croci D., Álvarez-Prado Á.F. et al., 2023/10/12. Cell, 186 (21) pp. 4546-4566.e27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_698367BEBBF8]
 
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff I.K., van den Bent M.J., Blumenthal D.T., Touat M., Peters K.B., Clarke J., Mendez J., Yust-Katz S., Welsh L., Mason W.P. et al., 2023/08/17. The New England journal of medicine, 389 (7) pp. 589-601. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3E3EF3CEF5]
Prediction of Glioma Grade and IDH Status Using <sup>18</sup>F-FET PET/CT Dynamic and Multiparametric Texture Analysis.
Hajri R., Nicod-Lalonde M., Hottinger A.F., Prior J.O., Dunet V., 2023/08/05. Diagnostics, 13 (15) p. 2604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9F508F3C03E3]
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C., Felsberg J., Gramatzki D., Le Rhun E., Clarke J., Soffietti R., Wick W., Chinot O., Ducray F., Roth P. et al., 2023/08. European journal of cancer, 189 p. 112913. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_58117B8EE829]
 
Clinical and Demographic Characteristics, Mechanisms, and Outcomes in Patients With Acute Ischemic Stroke and Newly Diagnosed or Known Active Cancer.
Costamagna G., Hottinger A., Milionis H., Lambrou D., Salerno A., Strambo D., Livio F., Navi B.B., Michel P., 2023/06/13. Neurology, 100 (24) pp. e2477-e2489. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3BF5CF7627]
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.
Wischnewski V., Maas R.R., Aruffo P.G., Soukup K., Galletti G., Kornete M., Galland S., Fournier N., Lilja J., Wirapati P. et al., 2023/06. Nature cancer, 4 (6) pp. 908-924. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF8A124C7797]
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M., Hundsberger T., Haefliger S., von Moos R., Hottinger A.F., Kaindl T., Engelhardt M., Marszewska M., Lane H., Roth P. et al., 2023/04. Investigational new drugs, 41 (2) pp. 267-275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8938B103AA5D]
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Álvarez-Prado Á.F., Maas R.R., Soukup K., Klemm F., Kornete M., Krebs F.S., Zoete V., Berezowska S., Brouland J.P., Hottinger A.F. et al., 2023/01/17. Cell reports. Medicine, 4 (1) p. 100900. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B718E4D7ABEC]
 
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K., Deckert M., Ferreri AJM, Furtner J., Gallego Perez-Larraya J., Henriksson R., Hottinger A.F., Kasenda B., Lefranc F., Lossos A. et al., 2023/01/05. Neuro-oncology, 25 (1) pp. 37-53. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E39A5D50A7EF]
2022
 
Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Zeitlberger A.M., Putora P.M., Hofer S., Schucht P., Migliorini D., Hottinger A.F., Roelcke U., Läubli H., Spina P., Bozinov O. et al., 2022/07. Journal of neuro-oncology, 158 (3) pp. 359-367. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8E6C586A4C96]
Prise en charge des métastases cérébrales en 2022 [Management of brain metastases in 2022]
Schiappacasse L., Kinj R., De Micheli R., Mederos N., Tuleasca C., Cossu G., Dunet V., Levivier M., Bourhis J., Hottinger A.F., 2022/05/18. Revue medicale suisse, 18 (782) pp. 976-983. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C341F49A8ECA]
 
Acute ischemic stroke in patients with newly diagnosed versus known active cancer: characteristics, mechanisms, and recurrences
Costamagna Gianluca, Hottinger Andreas, Milionis Haralampos, Salerno Alexander, Strambo Davide, Navi Babak, Michel Patrik (eds.), 2022/05., European Stroke Organisation Conference, 4-6 May 2022, Lyon, France, 7 1_suppl, European Stroke Journal .
[DOI][WoS][serval:BIB_14152F80D5B8]
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M., Ballo M.T., Bomzon Z., Urman N., Levi S., Lavy-Shahaf G., Jeyapalan S., Sio T.T., DeRose P.M., Misch M. et al., 2022/04/01. International journal of radiation oncology, biology, physics, 112 (5) pp. 1269-1278. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C099FBD4AC4]
 
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Mohile Nimish A, Messersmith Hans, Gatson Na Tosha N, Hottinger Andreas F, Lassman Andrew B, Morton Jordan, Ney Douglas, Nghiemphu Phioanh Leia, Olar Adriana, Olson Jeffery et al., 2022/03/12. Neuro-Oncology, 24 (3) pp. 358-383.
[DOI][WoS][serval:BIB_1B20FB31D2FA]
 
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile N.A., Messersmith H., Gatson N.T., Hottinger A.F., Lassman A., Morton J., Ney D., Nghiemphu P.L., Olar A., Olson J. et al., 2022/02/01. Journal of clinical oncology, 40 (4) pp. 403-426. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2B8FA515AE4E]
Neurologie [Neurology : what's new in 2021]
Vicino A., Allali G., Bally J., Castro Jimenez M., Chiabotti Salvioni P., Hirt L., Hottinger A., Michel P., Novy J., Pot Kreis C. et al., 2022/01/19. Revue medicale suisse, 18 (764-5) pp. 51-55. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A713627E7914]
Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of methe Phase 3 EF-14 Clinical Trial.
Ram Z., Kim C.Y., Hottinger A.F., Idbaih A., Nicholas G., Zhu J.J., 2022. Frontiers in oncology, 12 p. 902929. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC8D1F6C6D1E]
 
Diagnostic surveillance of high-grade gliomas: towards automated change detection using radiology report classification
Di Noto Tommaso, Atat Chirine, Teiga Eduardo Gamito, Hegi Monika, Hottinger Andreas, Bach Cuadra Meritxell, Hagmann Patric, Richiardi Jonas, 2022/01/01. pp. 423-436 dans Machine Learning and Principles and Practice of Knowledge Discovery in Databases. ECML PKDD 2021., Communications in Computer and Information Science. Peer-reviewed, Springer, Cham.
[DOI][serval:BIB_4653B6A7BD8C]
Transfer learning with weak labels from radiology reports: application to glioma change detection
Di Noto Tommaso, Bach Cuadra Meritxell, Atat Chirine, Gamito Teiga Eduardo, Hegi Monika, Hottinger Andreas, Hagmann Patric, Richiardi Jonas, 2022..
[URN][DOI][serval:BIB_9CC85EE111CA]
2021
 
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D., Barritault M., Montané L., Laigle-Donadey F., Chinot O., Le Rhun E., Bonneville-Levard A., Hottinger A.F., Meyronnet D., Bidaux A.S. et al., 2021/11/02. Neuro-oncology, 23 (11) pp. 1949-1960. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBD0E5E6E601]
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.
Cudalbu C., Bady P., Lai M., Xin L., Gusyatiner O., Hamou M.F., Lepore M., Brouland J.P., Daniel R.T., Hottinger A.F. et al., 2021/08/04. Acta neuropathologica communications, 9 (1) p. 133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB8B36AE633E]
 
Slowness Predicts Mortality: A Comparative Analysis of Walking Speed and Moberg Picking-Up Tests.
Meyer M.L., Fustinoni S., Henchoz Y., Hottinger A.F., Santos-Eggimann B., 2021/08. Journal of the American Medical Directors Association, 22 (8) pp. 1652-1657.e2. Peer-reviewed.
[DOI][Pmid][serval:BIB_C9E6961F8997]
Immunotherapy in Glioblastoma: A Clinical Perspective.
Desbaillets N., Hottinger A.F., 2021/07/24. Cancers, 13 (15) p. 3721. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_89F18E1BB4ED]
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice
Cudalbu C., Bady P., Lai M., Xin L., Gusyatiner O., Hamou MF, Lepore M., Brouland JP, Daniel RT, Hottinger AF et al., 2021/07/01..
[URN][DOI][serval:BIB_62503BCD223C]
 
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM).
Hofer S., Keller K., Imbach L., Roelcke U., Hutter G., Thomas H., Hertler C., Le Rhun E., Vasella F., Cordier D. et al., 2021/05/10. Swiss medical weekly, 151 pp. w20501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ADD1B8BB43E3]
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Klein M., Drijver A.J., van den Bent M.J., Bromberg J.C., Hoang-Xuan K., Taphoorn MJB, Reijneveld J.C., Ben Hassel M., Vauleon E., Eekers DBP et al., 2021/05/05. Neuro-oncology, 23 (5) pp. 803-811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_26325EFBDC53]
Neurologie [Recent Advances in Neurology]
Anichini A., Salvioni Chiabotti P., Bally J., Castro Jimenez M., Démonet J.F., Di Virgilio G., Hirt L., Hottinger A., Kuntzer T., Michel P. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 196-200. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_66C893415E17]
Diagnostic Surveillance of High-Grade Gliomas: Towards Automated Change Detection Using Radiology Report Classification
Tommaso Di Noto, Chirine Atat, Eduardo Gamito Teiga, Monika Hegi, Andreas Hottinger, Meritxell Bach Cuadra, Patric Hagmann, Jonas Richiardi, 2021. dans Machine Learning and Principles and Practice of Knowledge Discovery in Databases, Springer International Publishing.
[URN][DOI][serval:BIB_CD112344008E]
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z., Kim C.Y., Hottinger A.F., Idbaih A., Nicholas G., Zhu J.J., 2021. Frontiers in oncology, 11 p. 671972. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7B80528610A1]
 
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.
Wirsching H.G., Roelcke U., Weller J., Hundsberger T., Hottinger A.F., von Moos R., Caparrotti F., Conen K., Remonda L., Roth P. et al., 2021/01/01. Clinical cancer research, 27 (1) pp. 179-188. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DF2F9C55BFB]
 
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN, Barnholtz-Sloan J., Drappatz J., Henriksson R., Hottinger A.F., Hinoul P., Kruchko C., Puduvalli V.K., Tran D.D., Wong E.T. et al., 2021. Frontiers in oncology, 11 p. 679702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3821A19B0477]
 
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN, Barnholtz-Sloan J., Drappatz J., Henriksson R., Hottinger A.F., Hinoul P., Kruchko C., Puduvalli V.K., Tran D.D., Wong E.T. et al., 2021. Frontiers in oncology, 11 p. 679702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45FA8B6C595F]
2020
 
Physical approaches to treat glioblastoma.
Latifyan S., de Micheli R., Hottinger A.F., 2020/11. Current opinion in oncology, 32 (6) pp. 640-649. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80B7782807AE]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
Mohile N.A., Blakeley J.O., Gatson NTN, Hottinger A.F., Lassman A.B., Ney D.E., Olar A., Schiff D., Shih H.A., Strowd R. et al., 2020/07/22. Neuro-oncology, 22 (7) pp. 912-917. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F1C1BE3C2E7]
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Roth P., Hottinger A.F., Hundsberger T., Läubli H., Schucht P., Reinert M., Mamot C., Roelcke U., Pesce G., Hofer S. et al., 2020/06/01. Swiss medical weekly, 150 pp. w20256. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FDC3A4EA3596]
 
Glioma patient-reported outcome assessment in clinical care.
Tuleasca C., Knisely J., Leroy H.A., Hottinger A.F., Peciu-Florianu I., Levivier M., Reyns N., 2020/05. The Lancet. Oncology, 21 (5) pp. e230. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17C0FE6C449F]
Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.
Daccord C., Nicolas A., Demicheli R., Chehade H., Hottinger A.F., Beigelman C., Lazor R., 2020. Respiratory medicine case reports, 31 p. 101310. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D07C5F1D118C]
Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment.
Aícua-Rapún I., André P., Rossetti A.O., Ryvlin P., Hottinger A.F., Decosterd L.A., Buclin T., Novy J., 2020/01. Annals of neurology, 87 (1) pp. 22-29. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7737AA14ABFD]
2019
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Panje C.M., Putora P.M., Hundsberger T., Hottinger A.F., Roelcke U., Pesce G., Herrmann E., Matter-Walstra K., 2019/12/02. Swiss medical weekly, 149 pp. w20153. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F94BAF5F930]
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C48A9CE403D]
 
Malignant PRES and RCVS after brain surgery in the early postpartum period.
Cossu G., Daniel R.T., Hottinger A.F., Maduri R., Messerer M., 2019/10. Clinical neurology and neurosurgery, 185 p. 105489. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_023A53827800]
Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
Darlix A., Mandonnet E., Freyschlag C.F., Pinggera D., Forster M.T., Voss M., Steinbach J., Loughrey C., Goodden J., Banna G. et al., 2019/07. Neuro-oncology practice, 6 (4) pp. 264-273. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_075881197C02]
 
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C., Desbaillets N., Hottinger A.F., 2019/06. Current opinion in neurology, 32 (3) pp. 500-510. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8503B3CB45D8]
 
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.
Hottinger A.F., Bensaid D., De Micheli R., Moura B., Mokhtari K., Cardoso E., Idbaih A., Stupp R., 2019/01/01. Annals of oncology, 30 (1) pp. 155-156. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_54D10906FAA6]
2018
 
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
Wirsching H.G., Tabatabai G., Roelcke U., Hottinger A.F., Jörger F., Schmid A., Plasswilm L., Schrimpf D., Mancao C., Capper D. et al., 2018/06/01. Annals of oncology, 29 (6) pp. 1423-1430. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_385659ABD730]
 
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB, Dirven L., Kanner A.A., Lavy-Shahaf G., Weinberg U., Taillibert S., Toms S.A., Honnorat J., Chen T.C., Sroubek J. et al., 2018/04/01. JAMA oncology, 4 (4) pp. 495-504. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DEAA0BF555E3]
Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis.
Hottinger A.F., de Micheli R., Guido V., Karampera A., Hagmann P., Du Pasquier R., 2018/03. Neurology, 5 (2) pp. e439. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_936AFB128A84]
 
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Astaras C., de Micheli R., Moura B., Hundsberger T., Hottinger A.F., 2018/02/01. Current neurology and neuroscience reports, 18 (1) p. 3. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0037F78B4822]
2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A., Read W., Steinberg D.M., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K. et al., 2017/12/19. JAMA, 318 (23) pp. 2306-2316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_868908B10151]
 
Nouvelle classification OMS 2016 des gliomes : quels changements ? [Revised WHO classification 2016 of gliomas : what's new ?]
Brouland J.P., Hottinger A.F., 2017/10/18. Revue medicale suisse, 13 (579) pp. 1805-1809. Peer-reviewed.
[Pmid][serval:BIB_A56796E81114]
 
Extra central nervous system metastases from glioblastoma: a new possible trigger event?
Simonetti G., Silvani A., Fariselli L., Hottinger A.F., Pesce G.A., Prada F., Gaviani P., 2017/06/24. Neurological sciences, 38 (10) pp. 1873-1875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F947922E674]
 
Neurologie [Neurology]
Maulucci F., Benninger D., Démonet J.F., Du Pasquier R.A., Hirt L., Hottinger A., Kuntzer T., Michel P., Nater B., Novy J. et al., 2017/01/11. Revue medicale suisse, 13 (544-545) pp. 79-83. Peer-reviewed.
[Pmid][serval:BIB_C4707A08C4EF]
2016
Current management of low-grade gliomas.
Hottinger A.F., Hegi M.E., Baumert B.G., 2016/12. Current opinion in neurology, 29 (6) pp. 782-788. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AA45A63A4CB1]
 
Neurologic complications of immune checkpoint inhibitors.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) pp. 806-812. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F475869CA02A]
 
Neurooncology: a Swiss army knife specialty.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) p. 781. Peer-reviewed.
[DOI][Pmid][serval:BIB_D40536BC3C52]
Tumor treating fields: a novel treatment modality and its use in brain tumors.
Hottinger A.F., Pacheco P., Stupp R., 2016/10. Neuro-oncology, 18 (10) pp. 1338-1349. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1E5E2F0B2497]
 
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Espeli V., Ruegg E., Hottinger A.F., Modarressi A., Dietrich P.Y., 2016/05. Anticancer research, 36 (5) pp. 2359-2364. Peer-reviewed.
[Pmid][serval:BIB_FEB5E0F16A8A]
Prise en charge des tumeurs cérébrales primaires: une approche multidisciplinaire [Multidisciplinar approach to the management of gliomas]
Moura B., Migliorini D., Bourhis J., Roy D., Levivier M., Hottinger A.F., 2016/04/27. Revue medicale suisse, 12 (516) pp. 821-825. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_195E897B3E1C]
 
Recent advances in the management of atypical meningiomas.
Messerer M., Richoz B., Cossu G., Dhermain F., Hottinger A.F., Parker F., Levivier M., Daniel R.T., 2016/04. Neuro-Chirurgie, 62 (4) pp. 213-222. Peer-reviewed.
[DOI][Pmid][serval:BIB_FD65BBDB7034]
Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V., Pomoni A., Hottinger A., Nicod-Lalonde M., Prior J.O., 2016/03. Neuro-oncology, 18 (3) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C1621CCB076D]
Multilevel severe radiculopathy from an extraneural glioblastoma cervical metastasis.
Starnoni D., Yamgoué Y., Hottinger A., Bartanusz V., 2016. Surgical neurology international, 7 (Suppl 40) pp. S1028-S1029. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F6D8877E1A97]
 
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.
Hundsberger T., Hottinger A.F., Roelcke U., Roth P., Migliorini D., Dietrich P.Y., Conen K., Pesce G., Hermann E., Pica A. et al., 2016. Journal of Neuro-oncology, 126 (1) pp. 175-183. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_050325504608]
2015
 
Cerebriforms cells in cerebrum: an unusual finding
Sarro R., Gaide O., Letourneau A., Missiaglia E., Bisig B., Hottinger A., Cairoli A., de Leval L., 2015. p. 633 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_D23B3416D5B0]
 
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K., Bessell E., Bromberg J., Hottinger A.F., Preusser M., Rudà R., Schlegel U., Siegal T., Soussain C., Abacioglu U. et al., 2015. Lancet. Oncology, 16 (7) pp. e322-e332. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ADA57C554C83]
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L. et al., 2015. JAMA, 314 (23) pp. 2535-2543. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9E83CBEA38DC]
 
Recent developments and controversies in primary central nervous system lymphoma.
Hottinger A.F., Alentorn A., Hoang-Xuan K., 2015. Current Opinion In Oncology, 27 (6) pp. 496-501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_62BE86F4002F]
2014
 
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Hundsberger T., Tonder M., Hottinger A., Brügge D., Roelcke U., Putora P.M., Stupp R., Weller M., 2014. Journal of Neuro-Oncology, 118 (2) pp. 321-328.
[DOI][WoS][Pmid][serval:BIB_AA5EEA938557]
 
Isolated cerebral metastasis of a triceps muscle leiomyosarcoma: A case report.
Gautschi O.P., Hottinger A.F., Lobrinus J.A., Schaller K., Bijlenga P., 2014. British Journal of Neurosurgery, 28 (3) pp. 400-402.
[DOI][WoS][Pmid][serval:BIB_8419B9A83527]
 
Niedrig-gradige Gliome im Erwachsenenalter [Low-grade gliomas in adults].
Kratzsch T., Gautschi O.P., Kuhn S.A., Hottinger A.F., Hildebrandt G., Stienen M.N., 2014. Praxis, 103 (23) pp. 1385-1396. Peer-reviewed.
[DOI][Pmid][serval:BIB_3ECFB10F1079]
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Hottinger A.F., Aissa A.B., Espeli V., Squiban D., Dunkel N., Vargas M.I., Hundsberger T., Mach N., Schaller K., Weber D.C. et al., 2014. British Journal of Cancer, 110 (11) pp. 2655-2661.
[URN][DOI][WoS][Pmid][serval:BIB_A3EE92645B9C]
Standards of care and novel approaches in the management of glioblastoma multiforme.
Hottinger A.F., Stupp R., Homicsko K., 2014. Chinese Journal of Cancer, 33 (1) pp. 32-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCA412FE3838]
2013
 
Anticorps antineuronaux: un domaine en plein développement [Anti-neuronal antibodies: a rapidly developing field].
Zekeridou A., Rossetti A.O., Hottinger A.F., Du Pasquier R.A., 2013. Revue Médicale Suisse, 9 (384) pp. 909-914.
[Pmid][serval:BIB_50B33579B2CE]
 
Biphasic response of a teco-mesencephalic pylocitic astrocytoma after gamma knife surgery, a report of a case
Tuleasca C., Negretti L., Magaddino V., Maeder P., Hottinger A., Borruat F.X., Levivier M., 2013. dans 11th International Stereotactic Radiosurgery Society Congress.
[serval:BIB_7CF019F107A9]
 
High-grade meningiomas: new avenues for drug treatment?
Preusser M., Berghoff A.S., Hottinger A.F., 2013. Current Opinion in Neurology, 26 (6) pp. 708-715. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AAE72EE90D6C]
 
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A., Chan T.A., Abrey L.E., Khasraw M., Reiner A.S., Kaley T.J., DeAngelis L.M., Lassman A.B., Nolan C.P., Gavrilovic I.T. et al., 2013. Neuro-oncology, 15 (2) pp. 242-250.
[DOI][WoS][Pmid][serval:BIB_EC57AA6A44F7]
2012
 
A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.
Hottinger A.F., George A.C., Bel M., Favet L., Combescure C., Meier S., Grillet S., Posfay-Barbe K., Kaiser L., Siegrist C.A. et al., 2012. Oncologist, 17 (3) pp. 436-445. Peer-reviewed.
[DOI][Pmid][serval:BIB_9421CF11AB7C]
Decision making and management of gliomas: practical considerations.
Hottinger A.F., Homicsko K., Negretti L., Lhermitte B., Stupp R., 2012. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 23 Suppl 10 pp. x33-x40.
[URN][DOI][WoS][Pmid][serval:BIB_65E3046828D9]
2011
 
Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis.
Hottinger A.F., Favet L., Pache J.C., Martin J.B., Dietrich P.Y., 2011/04/06. Case reports in oncology, 4 (1) pp. 211-215. Peer-reviewed.
[DOI][Pmid][serval:BIB_6348A16FFE66]
 
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S., Elandt K., Greil R., Hottinger A.F., Huber U., Lemke D., Marosi C., Ochsenbein A., Pichler J., Roelcke U. et al., 2011. Acta Oncologica (stockholm, Sweden), 50 (5) pp. 630-635. Peer-reviewed.
[DOI][Pmid][serval:BIB_78DF1673CACD]
 
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.
Iwamoto F.M., Hottinger A.F., Karimi S., Riedel E., Dantis J., Jahdi M., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Journal of Neuro-oncology, 105 (3) pp. 607-612.
[DOI][Pmid][serval:BIB_976E612943E9]
 
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto F.M., Hottinger A.F., Karimi S., Riedel E., Dantis J., Jahdi M., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Neuro-oncology, 13 (11) pp. 1244-1251. Peer-reviewed.
[DOI][Pmid][serval:BIB_9B72410109E9]
 
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
Hottinger A.F., Iwamoto F.M., Karimi S., Riedel E., Dantis J., Park J., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Annals of Neurology, 70 (1) pp. 163-169. Peer-reviewed.
[DOI][Pmid][serval:BIB_94EF85011B9B]
2009
 
Neuro-oncology of Neurofibromatosis Type 1.
Hottinger A.F., Khakoo Y., 2009. Current Treatment Options In Neurology, 11 (4) pp. 306-314. Peer-reviewed.
[Pmid][serval:BIB_8B694172B9A0]
 
Neurological outcome of long-term glioblastoma survivors.
Hottinger A.F., Yoon H., DeAngelis L.M., Abrey L.E., 2009. Journal of Neuro-oncology, 95 (3) pp. 301-305. Peer-reviewed.
[DOI][Pmid][serval:BIB_1E2879532F95]
 
Neurooncology of familial cancer syndromes.
Hottinger A.F., Khakoo Y., 2009. Journal of Child Neurology, 24 (12) pp. 1526-1535. Peer-reviewed.
[DOI][Pmid][serval:BIB_D3850FC60544]
2008
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Stupp R., Hottinger A.F., van den Bent M.J., Dietrich P.Y., Brandes A.A., 2008. Annals of Oncology, 19 (Suppl 7) pp. vii209-vii216. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_77761A21F921]
 
Management of malignant glioma--quo vadis?
Stupp R., Hottinger A.F., 2008. Onkologie, 31 (6) pp. 300-302. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1457A298DB74]
 
Stratégies thérapeutiques pour le traitement des gliomes [Therapeutic strategies for the management of gliomas]
Hottinger A.F., Stupp R., 2008. Revue Neurologique, 164 (6-7) pp. 523-30. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ED8BD58F7EFF]
2007
 
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
Hottinger A.F., DeAngelis L.M., Yahalom J., Abrey L.E., 2007. Neurology, 69 (11) pp. 1178-1182. Peer-reviewed.
[DOI][Pmid][serval:BIB_194C77260E16]
 
Update on the management of familial central nervous system tumor syndromes.
Hottinger A.F., Khakoo Y., 2007. Current Neurology and Neuroscience Reports, 7 (3) pp. 200-207. Peer-reviewed.
[Pmid][serval:BIB_9D3A6769AB6F]
2005
 
Combined femoral and obturator neuropathy caused by synovial cyst of the hip.
Stuplich M., Hottinger A.F., Stoupis C., Sturzenegger M., 2005. Muscle and Nerve, 32 (4) pp. 552-554. Peer-reviewed.
[DOI][Pmid][serval:BIB_270DC5FB46F4]
2000
Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus.
Hottinger A.F., Azzouz M., Déglon N., Aebischer P., Zurn A.D., 2000/08. Journal of Neuroscience, 20 (15) pp. 5587-5593.
[URN][WoS][Pmid][serval:BIB_EEF5328332E6]
Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2
Azzouz M., Hottinger A., Paterna J. C., Zurn A. D., Aebischer P., Bueler H., 2000/03. Human Molecular Genetics, 9 (5) pp. 803-11.
[URN][DOI][WoS][Pmid][serval:BIB_F4FBC793D3AB]
1999
 
Cellular xenotransplantation.
Aebischer P., Hottinger A.F., Déglon N., 1999. Nature Medicine, 5 (8) p. 852.
[DOI][WoS][Pmid][serval:BIB_7F89061E0DC5]
 
Treatment of diseases of the central nervous system using encapsulated cells.
Hottinger A.F., Aebischer P., 1999. Advances and Technical Standards In Neurosurgery, 25 pp. 3-20. Peer-reviewed.
[Pmid][serval:BIB_A809B55D3131]
1997
 
The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
Hottinger A. F., Fine E. G., Gurney M. E., Zurn A. D., Aebischer P., 1997/07. European Journal of Neuroscience, 9 (7) pp. 1548-51.
[DOI][WoS][Pmid][serval:BIB_EFF4B728CC30]
1994
 
Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders.
Hof P.R., Nimchinsky E.A., Buée-Scherrer V., Buée L., Nasrallah J., Hottinger A.F., Purohit D.P., Loerzel A.J., Steele J.C., Delacourte A., 1994. Acta Neuropathologica, 88 (5) pp. 397-404. Peer-reviewed.
[Pmid][serval:BIB_4ED46FA7FF3F]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University